title: Current aspects of pulmonary arterial hypertension and therapeutics.
abstract: The pulmonary arterial hypertension (PAH) patients have high rate of mortality due to right ventricle (or ventricular) (RV) failures. A lot of research work is being carried out in the area, however no treatment is available that could contrast the rise in mortality rates in PAH patients. β1-adrenoceptor blockers (β-blockers, BB) reduced mortality in left heart failure, but they do not explored much at clinical level. Recent studies suggest β-blockers might be beneficial in PAH; however the mechanisms remain unknown. The present review article would put light on all these aspects of PAH along with latest ways for the management of PAH.
authors.affiliation: Xuzhou Central Hospital, Xuzhou, China.
authors.forename: Xianchi
authors.initials: X
authors.lastname: Li
authors.affiliation: Xuzhou Central Hospital, Xuzhou, China.
authors.forename: Yuanyuang
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Xuzhou Central Hospital, Xuzhou, China - cx07782434@163.com.
authors.forename: Peiying
authors.initials: P
authors.lastname: Zhang
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D019571:Arrhythmogenic Right Ventricular Dysplasia / Q000188:drug therapy / Q000209:etiology* / Q000628:therapy; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*
chemical_list: D000319:Adrenergic beta-Antagonists